Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May 12:13:97-106.
doi: 10.2147/IJNRD.S243210. eCollection 2020.

Efficacy and Safety of Evocalcet Evaluated by Dialysate Calcium Concentration in Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis

Takashi Shigematsu  1 , Shinji Asada  2 , Yuichi Endo  3 , Takehisa Kawata  2   3 , Masafumi Fukagawa  4 , Tadao Akizawa  5
Affiliations

Efficacy and Safety of Evocalcet Evaluated by Dialysate Calcium Concentration in Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis

Takashi Shigematsu et al. Int J Nephrol Renovasc Dis. .

Abstract

Purpose: Evocalcet is a novel oral calcimimetic drug that has demonstrated similar efficacy to cinacalcet in regulating serum parathyroid hormone (PTH), calcium, and phosphate levels, with fewer upper gastrointestinal tract-related adverse drug reactions (ADRs) in patients with secondary hyperparathyroidism undergoing hemodialysis in Japan. We investigated the efficacy and safety of once-daily oral evocalcet under different dialysate calcium concentrations.

Patients and methods: A post hoc analysis by dialysate calcium concentration (2.5, 2.75, and 3.0 mEq/L) was performed using data from a previous Phase 3 study that included cinacalcet as an active control. Efficacy endpoints were the proportion of patients who achieved the target intact PTH levels of ≥60 and ≤240 pg/mL between Week 28 and Week 30; time-course changes in serum intact PTH; calcium and phosphorus levels, bone turnover markers, and fibroblast growth factor 23 (FGF23) over the 30-week study period. Safety endpoints were overall ADRs and hypocalcemia- and upper gastrointestinal tract-related ADRs.

Results: A total of 634 patients were included in the analysis. Levels of intact PTH, calcium, phosphate, bone turnover markers, and FGF23 showed improvement in all sub-groups, irrespective of dialysate calcium concentration. The incidence of upper gastrointestinal tract-related ADRs was significantly lower in the evocalcet group than the cinacalcet group with dialysate calcium concentrations of 2.75 and 3.0 mEq/L (p<0.05 for both concentrations).

Conclusion: Evocalcet was effective and safe in regulating the levels of serum intact PTH, calcium, and phosphate in patients with secondary hyperparathyroidism undergoing hemodialysis, irrespective of dialysate calcium concentration.

Keywords: hypocalcemia; intact parathyroid hormone; oral calcimimetic; post hoc analysis; upper gastrointestinal tract.

PubMed Disclaimer

Conflict of interest statement

TS received consulting fees from KKC, Ono Pharmaceutical, Taisho Toyama Pharmaceutical, Fuji Pharma, and FUSO pharmaceutical industries, and lecture fees from KKC, Chugai Pharmaceutical, Bayer, Kissei Pharmaceutical, Torii Pharmaceutical, Ono Pharmaceutical, and FUSO pharmaceutical industries. SA, YE, and TK are employees of KKC. MF received consulting fees from KKC and Ono Pharmaceutical; lecture fees from KKC, Bayer, Torii Pharmaceutical, and Ono Pharmaceutical; and grants from KKC and Bayer. TA received consulting fees from KKC, Astellas Pharma, Bayer, Fuso Pharmaceutical, Japan Tobacco, Ono Pharmaceutical, Sanwa Chemical, Otsuka, GSK, and NIPRO, and lecture fees from KKC, Chugai Pharmaceutical, Bayer, Kissei Pharmaceutical, Torii Pharmaceutical, and Ono Pharmaceutical. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
Trends in mean intact PTH level (A) and mean percent change in intact PTH level (B) by dialysate calcium concentration in patients treated with evocalcet and cinacalcet. Abbreviation: PTH, parathyroid hormone.
Figure 2
Figure 2
Trends in mean serum corrected calcium (A) and phosphate (B) level by dialysate calcium concentration in patients treated with evocalcet and cinacalcet.
Figure 3
Figure 3
Incidence of hypocalcemia- (A) and upper gastrointestinal tract-related (B) adverse drug reactions by dialysate calcium concentration in patients treated with evocalcet and cinacalcet. Chi-square test.
See this image and copyright information in PMC

References

    1. Cunningham J, Locatelli F, Rodriguez M. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol. 2011;6:913–921. doi: 10.2215/CJN.06040710 - DOI - PubMed
    1. Komaba H, Kakuta T, Fukagawa M. Diseases of the parathyroid gland in chronic kidney disease. Clin Exp Nephrol. 2011;15:797–809. doi: 10.1007/s10157-011-0502-5 - DOI - PubMed
    1. Ketteler M, Block GA, Evenepoel P, et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) guideline update: what’s changed and why it matters. Kidney Int. 2017;92:26–36. doi: 10.1016/j.kint.2017.04.006 - DOI - PubMed
    1. Rodelo-Haad C, Rodríguez-Ortiz ME, Martin-Malo A, et al. Phosphate control in reducing FGF23 levels in hemodialysis patients. PLoS One. 2018;13:e0201537. doi: 10.1371/journal.pone.0201537 - DOI - PMC - PubMed
    1. Moe S, Drüeke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006;69:1945–1953. doi: 10.1038/sj.ki.5000414 - DOI - PubMed